Clinical Trial Update: A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating FCX-013 plus Veledimex in moderate to severe localized scleroderma (morphea) was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Localized Scleroderma
• Morphea
• Scleroderma

Drugs mentioned

• FCX-013 (FCX-013)
• Veledimex (Veledimex; small-molecule activator of the RheoSwitch Therapeutic System)

Snippet

Sponsor: Castle Creek Biosciences, LLC. | Conditions: Morphea, Scleroderma, Localized | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-06-24